Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

[1] Kruse V(2011)PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy Acta Clin Belg 66 2-9

[2] Rottey S(2013)Poly(ADP-ribose) polymerase inhibitors as cancer therapy Front Biosci (Landmark Ed) 18 1392-1406

[3] De Backer O(2011)PARP inhibitors: its role in treatment of cancer Chin J Cancer 30 463-471

[4] Van Belle S(2007)ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2728-2737

[5] Cocquyt V(2012)A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas Clin Cancer Res 18 1726-1734

[6] Denys H(2015)A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis Clin Cancer Res 21 68-76

[7] Hilton JF(2015)Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study J Neuro-Oncol 122 409-417

[8] Hadfield MJ(2012)Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 5588-5599

[9] Tran MT(2015)Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol Cancer Res 13 1465-1477

[10] Shapiro GI(2015)Profile of veliparib and its potential in the treatment of solid tumors Onco Targets Ther 8 1931-1939

[1] Kruse V(2011)PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy Acta Clin Belg 66 2-9

[2] Rottey S(2013)Poly(ADP-ribose) polymerase inhibitors as cancer therapy Front Biosci (Landmark Ed) 18 1392-1406

[3] De Backer O(2011)PARP inhibitors: its role in treatment of cancer Chin J Cancer 30 463-471

[4] Van Belle S(2007)ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2728-2737

[5] Cocquyt V(2012)A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas Clin Cancer Res 18 1726-1734

[6] Denys H(2015)A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis Clin Cancer Res 21 68-76

[7] Hilton JF(2015)Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study J Neuro-Oncol 122 409-417

[8] Hadfield MJ(2012)Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 72 5588-5599

[9] Tran MT(2015)Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol Cancer Res 13 1465-1477

[10] Shapiro GI(2015)Profile of veliparib and its potential in the treatment of solid tumors Onco Targets Ther 8 1931-1939